Molecular Therapy: Nucleic Acids (Jun 2024)

CRISPR-based editing strategies to rectify EYA1 complex genomic rearrangement linked to haploinsufficiency

  • Hwalin Yi,
  • Yejin Yun,
  • Won Hoon Choi,
  • Hye-Yeon Hwang,
  • Ju Hyuen Cha,
  • Heeyoung Seok,
  • Jae-Jin Song,
  • Jun Ho Lee,
  • Sang-Yeon Lee,
  • Daesik Kim

Journal volume & issue
Vol. 35, no. 2
p. 102199

Abstract

Read online

Pathogenic structure variations (SVs) are associated with various types of cancer and rare genetic diseases. Recent studies have used Cas9 nuclease with paired guide RNAs (gRNAs) to generate targeted chromosomal rearrangements, focusing on producing fusion proteins that cause cancer, whereas research on precision genome editing for rectifying SVs is limited. In this study, we identified a novel complex genomic rearrangement (CGR), specifically an EYA1 inversion with a deletion, implicated in branchio-oto-renal/branchio-oto syndrome. To address this, two CRISPR-based approaches were tested. First, we used Cas9 nuclease and paired gRNAs tailored to the patient’s genome. The dual CRISPR-Cas9 system induced efficient correction of paracentric inversion in patient-derived fibroblast, and effectively restored the expression of EYA1 mRNA and protein, along with its transcriptional activity required to regulate the target gene expression. Additionally, we used CRISPR activation (CRISPRa), which leads to the upregulation of EYA1 mRNA expression in patient-derived fibroblasts. Moreover, CRISPRa significantly improved EYA1 protein expression and transcriptional activity essential for target gene expression. This suggests that CRISPRa-based gene therapies could offer substantial translational potential for approximately 70% of disease-causing EYA1 variants responsible for haploinsufficiency. Our findings demonstrate the potential of CRISPR-guided genome editing for correcting SVs, including those with EYA1 CGR linked to haploinsufficiency.

Keywords